Latest news with #ClinicalTrials
Yahoo
2 days ago
- Business
- Yahoo
industryGENOME Unveils Groundbreaking Clinical Trial PAO Market Map Report, Powered by AI-Assisted Market Intelligence
TAMPA, Fla., June 30, 2025--(BUSINESS WIRE)--industryGENOME, a cutting-edge analytics firm specializing in granular precision insights, has released its first-ever Clinical Trial Patient Access Organization (PAO) Market Map Report, developed in collaboration with WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, and Crosstree. This report offers an unparalleled bottom-up analysis of the PAO sector, using AI-powered classification models to predict private company revenue and stratify market estimates across geographies, subsidiaries, and specialized capabilities. Transforming Industry Analysis with AI-Assisted Precision Leveraging its proprietary Industry Capabilities Classification System (ICCS®), industryGENOME provides a standardized and globally applicable framework for categorizing businesses. The ICCS® methodology enhances financial analysis, investment decision-making, and strategy development across the life sciences and healthcare industries. The report was developed in close collaboration with WCG, which played a pivotal role in identifying global industry participants to ensure the most comprehensive market representation. Crosstree assisted industryGENOME in industry classification quality assurance and predictive modeling, enhancing the precision of market insights. "This report is the most sophisticated analysis of the clinical trial PAO sector to date," said Shane Senior, Managing Director at Crosstree. "industryGENOME's AI-driven predictive engines achieve 85% classification accuracy, surpassing human classifiers, and ensuring the most precise industry intelligence for investors and market participants. The ability to scale this precision across large data sets is unprecedented." Key Findings from the Clinical Trial PAO Market Map Report Total Market Revenue: $14.95 billion Industry Participants: Over 3,000 global Patient Access Organizations with detailed company profiles for each Industry Stratification: Freestanding, Mobile, Virtual, Provider Embedded, and Service Embedded Sites Top Industry Players: Velocity, IQVIA, PPD, AES, CenExel Clinical Research, ERG, Javara Advanced Market Mapping: AI-assisted data collection and synthesis for high-fidelity revenue estimates allowing for "sum-of-the-parts" bottom-up market sizing Geo-Stratification Analysis: The United States leads with $10.6 billion in revenue, followed by the UK, Germany, and Australia Why This Report Sets a New Standard industryGENOME's bottom-up methodology, empowered by machine learning and predictive analytics, provides unprecedented insights into the PAO sector. The firm's mapped markets process, which identifies, collects, and analyzes micro-industry data, ensures highly precise revenue estimates, critical for investors, procurement specialists, and drug developers seeking strategic market positioning. Access the Report Today To access the Clinical Trial PAO Market Map Report, visit or contact Jordan Schiding at About industryGENOME industryGENOME is a market intelligence platform for the Health Sciences industry that continuously collects and analyzes millions of data points on pharma services companies, investors, deals, valuations, research, conferences, and news. It produces bottom-up market research reports and company profiles by combining AI with the expertise of industry investment professionals. The platform is distinguished by a proprietary, highly granular taxonomy that categorizes industry participant capabilities through defined relationships. This classification system delivers clean, precise, and actionable insights on the Health Sciences market. Using AI technologies—including natural language processing, machine translation, and supervised machine learning—industryGENOME classifies and curates data. In partnership with Crosstree, the platform trains its classification algorithm for accuracy and precision. Together, they are mapping the Health Sciences market one company at a time to deliver detailed, bottom-up industry segment insights. Learn more at About Crosstree Crosstree is a distinguished boutique investment banking firm focused exclusively on the needs of middle-market companies within three subsectors of the life sciences and healthcare industries: pharmaceutical services, diagnostics and tools, and digital health. Since 2004, Crosstree has advised on more completed transactions in these collective subsectors than any other investment bank. The firm provides clients a full suite of advisory and capital raising services, including both buy-and sell-side mergers and acquisitions advisory, private capital raising, strategic advisory, and valuations. Crosstree's narrow industry focus provides clients the expertise common of a bulge-bracket investment banking firm to middle-market companies and investors, with unparalleled industry insights, well-established strategic relationships across the globe and superior access to capital markets. From our offices in Tampa, Florida, Crosstree has advised clients throughout North America, Europe, India, China, Latin America, and Australia on transactions ranging from $25 million to more than $1 billion. About WCG WCG is at the forefront of accelerating clinical research worldwide, serving as the trusted and preferred partner to biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and site partners. Offering a unique combination of expertise, next-generation data and insights, and tech-enabled solutions, WCG reduces complexity and optimizes study operations and outcomes while maintaining the highest standards of human participant protection. For more than 55 years, WCG has maintained a relentless commitment to efficiency, safety, and impact, empowering clinical trials to deliver life-improving therapies swiftly. For more information, please visit or follow us on LinkedIn or X @WCGClinical. View source version on Contacts industryGENOME and Crosstree Media Contact: Hillary McCutcheonFreshwater Marketing813.992.1470hillary@ WCG Media Contact: Carmin Gade, PhDChief Marketing Officer, WCG484.351.9959cgade@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
25-06-2025
- Business
- Globe and Mail
Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing-Remitting Multiple Sclerosis Pipeline Report to explore emerging therapies, key Relapsing-Remitting Multiple Sclerosis Companies, and future Relapsing-Remitting Multiple Sclerosis treatment landscapes @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook Report Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report In June 2025, Novartis Pharmaceuticals announced a study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab. In June 2025, Celgene conducted a study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS). DelveInsight's Relapsing-Remitting Multiple Sclerosis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment. The leading Relapsing-Remitting Multiple Sclerosis Companies such as Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Promising Relapsing-Remitting Multiple Sclerosis Therapies such as TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others. Discover how the Relapsing-Remitting Multiple Sclerosis treatment paradigm is evolving. Access DelveInsight's in-depth Relapsing-Remitting Multiple Sclerosis Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing-Remitting Multiple Sclerosis Clinical Trials and Studies Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile IMU-838: Immunic AG Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Currently, the drug is in Phase III stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. IMCY-0141: Imcyse SA IMCY-0141 Imotope™ is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. ANK-700: Anokion SA ANK-700 is an investigational therapy developed by Anokion for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). It employs a novel approach known as an ""inverse vaccine,"" aiming to re-educate the immune system to recognize specific myelin proteins as ""self,"" thereby preventing autoimmune attacks on the central nervous system. This strategy seeks to reduce neuroinflammation while preserving overall immune function. Anokion's approach utilizes its proprietary immune tolerance platform, which targets natural pathways in the liver to restore immune tolerance. This liver-targeted antigen strategy effectively expands antigen-specific regulatory T-cells in vivo, offering therapeutic potential across various inflammatory conditions, including multiple sclerosis. ANK-700's innovative mechanism and encouraging early clinical data position it as a promising candidate for future disease-modifying therapies in RRMS. Currently, the drug is in Phase I stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. The Relapsing-Remitting Multiple Sclerosis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing-Remitting Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis Treatment. Relapsing-Remitting Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Relapsing-Remitting Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing-Remitting Multiple Sclerosis market. Get a detailed analysis of the latest innovations in the Relapsing-Remitting Multiple Sclerosis pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing-Remitting Multiple Sclerosis Unmet Needs Relapsing-Remitting Multiple Sclerosis Companies Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Relapsing Remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Relapsing-Remitting Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing-Remitting Multiple Sclerosis Therapies and key Relapsing-Remitting Multiple Sclerosis Developments @ Relapsing-Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report Coverage- Global Relapsing-Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Relapsing-Remitting Multiple Sclerosis Therapies- TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others. Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Relapsing-Remitting Multiple Sclerosis drug development? Find out in DelveInsight's exclusive Relapsing-Remitting Multiple Sclerosis Pipeline Report—access it now! @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Relapsing-Remitting Multiple Sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Relapsing-Remitting Multiple Sclerosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic AG Drug profiles in the detailed report….. Mid Stage Products (Phase II) Telitacicept: RemeGen Drug profiles in the detailed report….. Early Stage Products (Phase I) ANK700: Anokion Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Relapsing-Remitting Multiple Sclerosis Key Companies Relapsing-Remitting Multiple Sclerosis Key Products Relapsing-Remitting Multiple Sclerosis- Unmet Needs Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion Relapsing-Remitting Multiple Sclerosis Analyst Views Relapsing-Remitting Multiple Sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
25-06-2025
- Health
- Yahoo
AI & ML in Clinical Trials: Fundamentals, Applications, and Regulatory Aspects - One-Day Training Course on 30th June 2025: Master AI & ML Applications in Clinical Research
Unlock the future of clinical trials with this one-day course on AI & ML. Dive into their role in trial optimization, ethical challenges, and regulatory compliance, including EU AI Act insights. Learn through real-world case studies and gain CPD certification. Enhance your skill set now! Dublin, June 25, 2025 (GLOBE NEWSWIRE) -- The "AI & ML in Clinical Trials: Fundamentals, Applications, and Regulatory Aspects Training Course (ONLINE EVENT: June 30, 2025)" has been added to offering. Artificial Intelligence (AI) and Machine Learning (ML) are rapidly reshaping the clinical trials landscape, driving innovation in how research is designed, conducted and evaluated. While these technologies hold immense promise to enhance efficiency, reduce costs, and improve outcomes, their adoption is paired with ethical concerns, prompting the development of robust regulatory frameworks to guide their responsible use. For professionals in the field, understanding the fundamentals of AI and ML and their implications is becoming increasingly essential. This comprehensive one-day training course provides an overview of AI and ML, focusing on their applications in clinical trials and the regulatory and ethical considerations that accompany their use. Participants will explore how AI and ML are being used to optimize trial efficiency, predict patient outcomes, and support adaptive trial designs. The course will also examine the regulatory frameworks, including the EU AI Act and related regulatory initiatives, to ensure compliance and ethical use of these technologies in a highly regulated environment. Through engaging lectures, real-world case studies, and interactive assessments, attendees will gain valuable insights into the transformative potential of AI and ML in clinical trials while understanding the challenges and responsibilities associated with their implementation. Join us to enhance your knowledge of these cutting-edge technologies and their role in advancing clinical research. Benefits of attending Explore the fundamental concepts of AI and ML Learn how to address common challenges with cutting-edge solutions Explore real-world use cases of AI-powered tools for clinical trial optimization Understand the ethical and regulatory requirements essential to adopting AI in clinical settings Reflect on change management in people, process, and tools for implementing an AI-based tools Prepare for the future of clinical trials and stay ahead of industry advancements Certifications: CPD: 6 hours for your records Certificate of completion Who Should Attend: This course is aimed at anyone working in clinical research, clinical operations, data management, regulatory and compliance, and associated functions seeking to leverage AI and ML in clinical trials. Whether you're new to AI/ML or looking to deepen your understanding, this course provides valuable insights into how these technologies are reshaping the clinical research landscape. Course Agenda: Introduction to AI and ML Key concepts and terminologies Types of machine learning Applications in healthcare, trends, and innovations Applications of AI and ML in clinical trials Opportunities and challenges Real-world data analysis Trial design and simulation Patient recruitment and retention optimization Predictive modelling for outcomes Applications of AI and ML in clinical trials cont'd Patient monitoring and safety surveillance Clinical data management and analysis Workflow optimization Regulatory landscape for AI in clinical trials Overview of FDA, EMA, and other relevant agencies' positions on AI and ML Validation and approval processes for AI-based tools Requirements for data handling and reporting Ethical aspects Transparency, fairness, and accountability Mitigating bias in AI models Balancing innovation with patient safety Integration and future directions Steps to incorporate AI into clinical trial workflows Overcoming common obstacles in AI/ML adoption Future directions For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
The Independent
21-06-2025
- Health
- The Independent
New daily weight loss pill to rival injections
A new daily Weight Loss pill, amycretin, developed by Novo Nordisk, has shown promising results in initial studies. In trials, patients receiving weekly amycretin injections lost an average of 24.3 percent of their body weight over 36 weeks. Patients taking daily amycretin tablets achieved an average w eight loss of 13.1 percent over 12 weeks. Amycretin works by targeting GLP-1 and amylin receptors to help control blood sugar and appetite. Side effects, including nausea and vomiting, were reported as mostly mild to moderate and resolved by the end of treatment.
Yahoo
19-06-2025
- Business
- Yahoo
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared Booth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes ACTON, Mass., June 19, 2025--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 85th Scientific Sessions taking place June 20 – 23, 2025 at the McCormick Place Convention Center in Chicago, Illinois. "We are thrilled to share more details that dive deeper into the clinical outcomes from our groundbreaking SECURE-T2D and RADIANT trials, as well as the real-world outcomes we are seeing, especially with type 2 diabetes," said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet Senior Vice President and Chief Medical Officer. "We are also looking forward to many conversations with healthcare providers about what the outcomes mean, with practical insights on how to optimize therapy." Insulet shared results of the first large pivotal trial of Automated Insulin Delivery (AID) in type 2 diabetes (SECURE-T2D) at last year's ADA conference. In March, Insulet presented results of the first randomized controlled trial to assess the direct transition from multiple daily injections (MDI) to AID in adults and children with type 1 diabetes not meeting glycemic targets with injections (RADIANT). Presentations at ADA this week will provide richer insights into both trials and more. Conference Activities: Dr. Ly will lead a panel discussion, "Setting the Standard with Omnipod 5: Remarkable Results with Unmatched Simplicity," on Sunday, June 22 from 10:15 – 11:00 AM CT in the conference product theater. She will be joined by Dr. Anders L. Carlson, MD, Associate Executive Director, International Diabetes Center, Director, HealthPartners Diabetes Program, and Associate Professor, University of Minnesota Medical School; Dr. Gregory Forlenza, MD, MS, Associate Professor of Pediatrics, Director of Pediatric Diabetes Technology Research, Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus; and Dr. Emma Wilmot, MB ChB BSc (hons), PhD, FRCP, Associate Professor, University of Nottingham, Honorary Consultant Diabetologist, University Hospitals of Derby and Burton NHS Trust, Royal Derby Hospital UK. They will have an interactive conversation around several thought-provoking case studies designed to challenge conventional thinking and therapeutic approaches. Dr. Ly will also provide a high-level overview of Insulet's innovation roadmap. Additionally, on Saturday, June 21, there will be a Diabetes Learning Byte session, "Go Beyond GLP-1 Therapy in Type 2 Diabetes with Omnipod 5," from 11:00 AM – 11:20 AM CT at booth 927 with Davida F. Kruger, MSN, APN-BC, BC-ADM, Certified Nurse Practitioner, Henry Ford Health Division of Endocrinology, Diabetes, Bone and Mineral Disease; and Leslie Barrett, MS, RD, CDCES, Director of Medical Affairs, Insulet. Oral Presentations Friday, June 20, Session: 5:30 – 6:30 PM CT, Presentation 5:45 – 6:00 PM CT (W184A-D) 130-OR– Real-World Glycemic Outcomes in Adults with Type 2 Diabetes (T2D) Using the Omnipod 5 Automated Insulin Delivery (AID) System with Dr. Sean Oser Saturday, June 21, Session: 1:30 – 3:00 PM CT, Presentation 2:00 – 2:15 PM CT (W185A-D) 155-OR– Reduced Perceived Diabetes Distress with the Omnipod 5 Automated Insulin Delivery (AID) System in Adults with Type 2 Diabetes (T2D) – Analysis of the SECURE-T2D Study with Dr. Kristin Castorino Monday, June 23, Session: 1:30 – 3:00 PM CT, Presentation 2:45 – 3:00 PM CT (W183A) 314-OR– Improved Outcomes Across Baseline Time-in-Range Levels with the Omnipod 5 AID System Compared with Multiple Daily Injections (MDI) in Type 1 Diabetes (T1D): Analysis of the RADIANT Study with Dr. Emma Wilmot Poster Presentations The following poster presentations will be held from 12:30 – 1:30 PM CT in the Poster Hall (Hall F1) during the weekend. Saturday, June 21 [945-P] – Improved Glycemic Outcomes with the Omnipod 5 AID System in Adults with Type 2 Diabetes (T2D) Previously Using Basal without Bolus Insulin: Sub-analysis of the SECURE-T2D Study with Dr. Anders Carlson [937-P] – Successful Transition from Multiple Daily Injections (MDI) to Automated Insulin Delivery (AID): Real-world Glycemic Outcomes among People with Diabetes Using the Omnipod AID System with Dr. Grazia Aleppo [958-P] – Impact of Insulin Therapy Technology on Health-Related Quality of Life in Adults with Type 1 Diabetes: A Health Utility Study of Five Forms of Therapy with Colin Hopley, MPH, Insulet Sunday, June 22 [2011-LB] – iPhone App Adoption Improves Bolusing Frequency in Adolescents and Young Adults with Type 1 Diabetes (T1D): Insights from Real-World Omnipod® 5 Automated Insulin Delivery (AID) System Use with Dr. Gregory Forlenza Booth Activities: Podcast recordings for Beyond the Bolus, Within Range will be conducted from Insulet's booth (1218). Also, a Baird hosted webcast, "ADA Recap Interview with Dr. Trang Ly," will be facilitated by Sr. Research Analyst, Jeff Johnson. This will take place on Monday, June 23, at 11:00 AM CT. The interview will feature a recap of highlights, new clinical data, and updates from ADA. A link to the webcast will be available on the Investor Relations section of the Company's website at under "Events and Presentations," and will be archived for future replay. Insulet will bring immersive booth experiences that showcase how Omnipod 5 is transforming diabetes management. Attendees can engage in hands-on demonstrations led by clinical experts, exploring optimization techniques that support better outcomes. Attendees can also play an educational trivia game to learn how Omnipod 5 brings a whole new level of simplicity and convenience for mealtime insulin dosing. Insulet will also be distributing a new comic book to celebrate representation for the diabetes community. Dyasonic: Sound of Strength featuring a hero with type 1 diabetes. To access the comic book and related materials go to About Insulet Corporation: Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet's flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit: and ©2025 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation. View source version on Contacts Investor Relations: June LazaroffSenior Director, Investor Relations(978) 600-7717jlazaroff@ Media: Angela Geryak WiczekSenior Director, Corporate Communications(978) 932-0611awiczek@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
